Published in Cancer Sci on June 21, 2016
Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications. Ther Adv Med Oncol (2017) 0.75
Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI. J Thorac Dis (2017) 0.75
Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients. Oncotarget (2017) 0.75
Evaluation of digital PCR for detecting low-level EGFR mutations in advanced lung adenocarcinoma patients: a cross-platform comparison study. Oncotarget (2017) 0.75
Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. Surg Today (2017) 0.75
Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma. PLoS One (2017) 0.75
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 27.12
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med (2015) 7.11
Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med (2015) 6.28
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res (2013) 6.10
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol (2009) 5.70
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov (2014) 4.55
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res (2011) 4.16
Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol (2012) 2.91
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer (2015) 1.78
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol (2011) 1.71
An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol (2012) 1.63
Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. Lung Cancer (2014) 1.21
The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. Cancer (2014) 1.05
Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI. J Thorac Oncol (2015) 1.02
Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01). Lung Cancer (2014) 1.00
Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications. Radiology (2012) 0.97
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). Clin Cancer Res (2016) 0.90
Real world impact of epidermal growth factor receptor mutation status on treatment patterns in patients with non-small cell lung cancer. Lung Cancer (2013) 0.78
Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. Lancet Oncol (2015) 1.62
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. Lancet Respir Med (2016) 0.96
Organizing Pneumonia Induced by Nivolumab in a Patient with Metastatic Melanoma. J Thorac Oncol (2015) 0.94
Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer. Ann Thorac Med (2015) 0.94
Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison. Clin Colorectal Cancer (2016) 0.90
Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102. Clin Colorectal Cancer (2016) 0.85
Identification of metabolic signatures associated with erlotinib resistance of non-small cell lung cancer cells. Anticancer Res (2014) 0.84
Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group. Cancer Sci (2014) 0.83
A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer (2016) 0.82
Outcomes of initial surgery in patients with clinical N2 non-small cell lung cancer who met 4 specific criteria. Surg Today (2015) 0.81
Does Repeated Lung Resection Provide Long-Term Survival for Recurrent Pulmonary Metastases of Colorectal Cancer? Results of a Retrospective Japanese Multicenter Study. Ann Thorac Surg (2016) 0.80
A favorable clinical effect of an expectorant in allergic bronchopulmonary mycosis caused by Schizophyllum commune. Respir Med Case Rep (2016) 0.78
Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol (2017) 0.75
Phase I study of Efatutazone, an oral PPARγ agonist, in patients with metastatic solid tumors. Anticancer Res (2014) 0.75
"Comet tail sign": A pitfall of post-gadolinium magnetic resonance imaging findings for metastatic brain tumors. J Neurooncol (2016) 0.75
Surgical Outcome and Prognostic Stratification for Pulmonary Metastasis from Colorectal Cancer. Ann Thorac Surg (2017) 0.75
A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy. Jpn J Clin Oncol (2017) 0.75
Complete Resection of Masaoka Stage IVb Thymic Carcinoma After Chemoradiotherapy. Ann Thorac Surg (2017) 0.75
Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy. Invest New Drugs (2017) 0.75
A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC. JTO Clin Res Rep (2021) 0.75
Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer. Int J Clin Oncol (2017) 0.75
Boundary between N1 and N2 Lymph Node Descriptors in the Subcarinal Zone in Lower Lobe Lung Cancer: A Brief Report. J Thorac Oncol (2016) 0.75
The Effects of Advanced Age and Serum α1 -Acid Glycoprotein on Docetaxel Unbound Exposure and Dose-limiting Toxicity in Cancer Patients. Br J Clin Pharmacol (2017) 0.75
Peritoneal dissemination in early gastric cancer: importance of the lymphatic route. Virchows Arch (2016) 0.75
Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401). J Thorac Oncol (2017) 0.75
Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity. Lung Cancer (2016) 0.75
Risk factors for lymph node metastasis and long-term outcomes of patients with early gastric cancer after non-curative endoscopic submucosal dissection. Surg Endosc (2016) 0.75
Variation in (18)F-FDG PET findings in a patient with synchronous multiple thymoma. Gen Thorac Cardiovasc Surg (2013) 0.75
Modified GAP index for prediction of acute exacerbation of idiopathic pulmonary fibrosis in non-small cell lung cancer. Respirology (2017) 0.75
"Direct MPR": A Useful Tool for Oblique CT Fluoroscopy-Assisted Puncture. Cardiovasc Intervent Radiol (2017) 0.75
A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index. Cancer (2022) 0.75
Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011). Lung Cancer (2017) 0.75
The concept of platinum sensitivity could be applied to recurrent cervical cancer: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group. Cancer Chemother Pharmacol (2017) 0.75
Sorafenib versus Hepatic Arterial Infusion Chemotherapy as Initial Treatment for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombosis. Liver Cancer (2017) 0.75
Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer. ESMO Open (2017) 0.75
A prospective, multi-institutional phase II study of induction chemoradiotherapy followed by surgery in patients with non-small cell lung cancer involving the chest wall (CJLSG0801). Lung Cancer (2016) 0.75
Outcomes of segmentectomy and wedge resection for pulmonary metastases from colorectal cancer. Eur J Cardiothorac Surg (2016) 0.75